Bruker (BRKR) Aperçu de l'action
Bruker Corporation, avec ses filiales, développe, fabrique et distribue des instruments scientifiques et des solutions analytiques et diagnostiques. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
BRKR Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bruker Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$43.85 |
| Plus haut sur 52 semaines | US$56.22 |
| Plus bas sur 52 semaines | US$28.53 |
| Bêta | 1.12 |
| Variation sur 1 mois | 12.29% |
| Variation sur 3 mois | 16.90% |
| Variation sur 1 an | 19.00% |
| Variation sur 3 ans | -40.95% |
| Variation sur 5 ans | -34.83% |
| Évolution depuis l'introduction en bourse | 90.14% |
Nouvelles et mises à jour récentes
Recent updates
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaBRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture
The market for Bruker Corporation's ( NASDAQ:BRKR ) shares didn't move much after it posted weak earnings recently. We...Rendement pour les actionnaires
| BRKR | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | 3.7% | -4.7% | 0.5% |
| 1Y | 19.0% | 3.8% | 25.4% |
Rendement vs Industrie: BRKR a dépassé le secteur US Life Sciences qui a rapporté 3.8 % au cours de l'année écoulée.
Rendement vs marché: BRKR a sous-performé le marché US qui a rapporté 25.4 % au cours de l'année écoulée.
Volatilité des prix
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: BRKR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de BRKR ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation, avec ses filiales, développe, fabrique et distribue des instruments scientifiques et des solutions analytiques et diagnostiques. Elle opère à travers quatre segments : Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano et Bruker Energy & Supercon Technologies. La société propose des solutions de spectroscopie par résonance magnétique, d'imagerie préclinique, biopharmaceutique et appliquée, de services et d'assistance tout au long du cycle de vie, de solutions de données intégrées et d'automatisation ; des outils pour les sciences de la vie ; des produits innovants de résonance magnétique nucléaire (RMN) et de résonance paramagnétique électronique (RPE) ; des solutions pour les processus in vivo et la découverte de médicaments ; des solutions après-vente ; des solutions pour l'automatisation et la numérisation des laboratoires ; des solutions de spectrométrie de masse et des kits de test, des bandelettes de test ADN et des technologies PCR basées sur la fluorescence ; des kits de diagnostic moléculaire de génotype et de fluorotype ; et des instruments et solutions de recherche, d'analyse et d'analyse des processus.
Bruker Corporation Résumé des fondamentaux
| BRKR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$6.81b |
| Bénéfices(TTM) | -US$36.40m |
| Recettes(TTM) | US$3.46b |
Le site BRKR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BRKR compte de résultat (TTM) | |
|---|---|
| Recettes | US$3.46b |
| Coût des recettes | US$1.81b |
| Marge brute | US$1.65b |
| Autres dépenses | US$1.68b |
| Les revenus | -US$36.40m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.24 |
| Marge brute | 47.62% |
| Marge bénéficiaire nette | -1.05% |
| Ratio dettes/capitaux propres | 67.4% |
Quelles ont été les performances à long terme de BRKR?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/13 09:05 |
| Cours de l'action en fin de journée | 2026/05/13 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bruker Corporation est couverte par 29 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |